Sep 02, 2025
Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer's disease and Dementia Data
Jul 31, 2025
Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025
Jun 13, 2025
Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'
May 21, 2025
Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'
Feb 26, 2025
Neurophet Presented Three Research Abstracts on Personalized tDCS at International Brain Stimulation Conference
Dec 05, 2024
Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA
Nov 25, 2024
Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA'
Nov 15, 2024
Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth
Oct 30, 2024
Neurophet partners with Beijing LADO Technology... Intends to establish Joint Venture in China
Oct 18, 2024
Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.
Oct 15, 2024
Neurophet-AriBio to develop 'Next-Gen Platform for Alzheimer's diagnosis'
Sep 09, 2024
Neurophet-NTU Singapore, recognized for outstanding joint research
Jul 25, 2024
Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024
Jun 26, 2024
Neurophet to present brain stimulation simulation study at OHBM 2024
May 31, 2024
Neurophet to participate BIO USA... exploring global partnership and business